CoChat

Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

Open access
Siu, Man Kit, Abou-Kheir, Wassim, Yin, Juan Juan, Chang, Yung-Sheng, Barrett, Ben, Suau, Florent, Casey, Orla, Chen, Wei-Yu, Fang, Lei, Hynes, Paul, Hsieh, Yao-Yu, Liu, Yen-Nien, Huang, Jiaoti, Kelly, Kathleen · 2014 · Oncotarget
Cited by 62

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// Man Kit Siu 1,2,* , Wassim Abou-Kheir 3,* , Juan Juan Yin 4,* , Yung-Sheng Chang 1 , Ben Barrett 4 , Florent Suau 4 , Orla Casey 4 , Wei-Yu Chen 5 , Lei Fang 4 , Paul Hynes 4 , Yao-Yu Hsieh 1,6,9 , Yen-Nien Liu 1,7 , Jiaoti Huang 8 and Kathleen Kelly 4 1 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan 2 Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 3 Department of Anatomy, Cell Biology and Physiological Sciences Faculty of Medicine, American University of Beirut, Beirut, Lebanon 4 Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 5 Department of Pathology, Wan Fang Hospital, College of Medicine, Taipei Medical University, Taipei, Taiwan 6 Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan 7 Center of Excellence for Cancer Research, Wan Fang Hospital, College of Medicine, Taipei Medical University, Taipei, Taiwan 8 Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA 9 Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan * These authors contributed equally to this work Correspondence: Yen-Nien Liu, email: // Keywords : Bone metastasis/Epidermal growth factor receptor (EGFR)/Prostate cancer/miR-203 /KRAS/Tyrosine kinase inhibitors (TKIs) resistance Received : February 20, 2014 Accepted : May 18, 2014 Published : May 20, 2014 Abstract Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies targeting EGFR have demonstrated limited effectiveness and led to drug resistance. miR-203 levels are down-regulated in clinical samples of primary prostate cancer and further reduced in metastatic prostate cancer. Here we show that ectopic miR-203 expression displayed reduced bone metastasis and induced sensitivity to tyrosine kinase inhibitors (TKIs) treatment in a xenograft model. Our results demonstrate that the induction of bone metastasis and TKI resistance require miR-203 down-regulation, activation of the EGFR pathway via altered expression of EGFR ligands ( EREG and TGFA ) and anti-apoptotic proteins (API5, BIRC2, and TRIAP1). Importantly, a sufficient reconstitution of invasiveness and resistance to TKIs treatment was observed in cells transfected with anti-miR-203. In prostate cancer patients, our data showed that miR-203 levels were inversely correlated with the expression of two EGFR ligands, EREG and TGFA, and an EGFR dependent gene signature. Our results support the existence of a miR-203, EGFR, TKIs resistance regulatory network in prostate cancer progression. We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metastasis and TKIs resistance characterized by high EGFR ligands output and anti-apoptotic proteins activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1994

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Siu, M. K., Abou-Kheir, W., Yin, J. J., Chang, Y.-S., Barrett, B., Suau, F., Casey, O., Chen, W.-Y., Fang, L., Hynes, P., Hsieh, Y.-Y., Liu, Y.-N., Huang, J., & Kelly, K.
Venue
Oncotarget
Published
2014-05-20
Volume
5
Issue
11
Pages
3770-3784
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2096504277
Cited by
62
References
6
FWCI
2.82
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.